Table 2

Association of genetic polymorphisms with the risk of ovarian cancer

GenotypeaCasesControlsORb95% CIP for trendc
No.(%)No.(%)
CYP1A1 (MspI)
m1/m154(44)76(53)1d
m1/m254(44)47(33)1.40.8–2.5
m2/m214(11)21(14)0.80.3–1.90.74
CYP1A1 (Ile/Val)
A/A90(73)102(71)1d
A/G29(23)34(24)0.80.4–1.5
G/G5(4)8(5)0.60.2–2.00.42
CYP1A2
A/A73(63)67(49)1d
A/C37(32)58(42)0.60.4–1.1
C/C6(5)13(9)0.50.2–1.60.11
CYP1B1
Val/Val13(10)7(5)3.81.2–11.40.005
Val/Leu48(38)42(29)1.81.0–3.3
Leu/Leu67(52)95(66)1d
COMT
Val/Val52(42)68(47)1d
Val/Met57(46)57(40)1.30.8–2.3
Met/Met16(13)19(13)0.90.4–2.00.71
  • a Genotyping data for cases and controls, respectively, were missing for the following polymorphisms: CYP1A1(MspI) 7, 0; CYP1A1 (Ile/Val) 5, 0; CPY1A2 13, 6; CYP1B11, 0; and COMT 4, 0.

  • b Adjusted by multiple unconditional logistic regression for age, ethnicity, education, pregnancy history, oral contraceptive pill use, history of tubal ligation, and regularity of menstrual cycles.

  • c Based on the likelihood ratio test comparing models with and without a trend variable, assigned values 1, 2, and 3 to the subgroups with 0, 1, and 2 alleles of interest.

  • d Reference category. The Val/Val group was used for CYP1B1 because of the small numbers in the Leu/Leu group.